Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1391&sort=award_id
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_id", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=award_id", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=award_id", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1390&sort=award_id" }, "data": [ { "type": "Grant", "id": "9407", "attributes": { "award_id": "75N91021C00002-0-9999-1", "title": "THE CONTRACTOR SHALL DEVELOP AN INFRASTRUCTURE TO INTEGRATE VARIOUS TYPES OF REAL WORLD DATA FROM A VARIETY OF CLINICAL AND NONCLINICAL SOURCES IN ORD", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-12-11", "end_date": "2021-12-10", "award_amount": 3492171, "principal_investigator": { "id": 25137, "first_name": "SANDY", "last_name": "LEONARD", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1830, "ror": "", "name": "HEALTHVERITY, INC.", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1830, "ror": "", "name": "HEALTHVERITY, INC.", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "The objective of this contract is to develop infrastructure to collect data of various types and from various sources in order to perform critical analyses using an integrated set of linked data representing commercial longitudinal laboratory test results at the patient level for SARS CoV-2 Nucleic Acid Amplification Test (NAAT) and antibody testing to assess the impact of known SARS-CoV-2 seropositivity on the rate of subsequent re-infection with a cohort study design using Real World Data (RWD). The data will be analyzed to determine whether antibodies to SARS-CoV-2 are protective against re-infection, and if so, how long that protection last. While vaccine-related clinical trials are underway, results are likely to be slower than potential analyses using RWD. The cohort is defined as all patients tested for SARS-CoV-2 antibodies that can be followed longitudinally (for a minimum of one year). The longitudinal analysis will be conducted using data from commercial lab test results linked to data (beginning with data pulled from January 2020 through present with monthly downloads to the Government for the Period of Performance over four months) from claims for inpatient, outpatient and pharmacy data, hospital chargemaster data representing detailed services received during an inpatient hospital admission, and EMR data from outpatient facilities both integrated with a health care system as well as for community practices.", "keywords": [ "2019-nCoV", "Asthma", "Cardiovascular Diseases", "Chronic Obstructive Airway Disease", "Clinical", "Clinical Trials", "Cohort Studies", "Community Practice", "Contractor", "Contracts", "Data", "Demographic Factors", "Diabetes Mellitus", "Diagnostic tests", "Geographic Locations", "Government", "Healthcare Systems", "Hospitalization", "Hospitals", "Hypertension", "Immune System Diseases", "Impairment", "Infection", "Infrastructure", "Inpatients", "Kidney", "Laboratories", "Link", "Malignant Neoplasms", "Nucleic Acid Amplification Tests", "Nursing Homes", "Obesity", "Occupations", "Outpatients", "Patients", "Pattern", "Performance", "Pharmacy facility", "Pilot Projects", "Relative Risks", "Research Design", "Risk", "SARS-CoV-2 antibody", "SARS-CoV-2 infection", "SARS-CoV-2 positive", "Serology test", "Services", "Source", "Test Result", "Testing", "Time", "Vaccines", "antibody test", "base", "cohort", "comorbidity", "infection rate", "longitudinal analysis", "outpatient facility", "primary outcome", "residence", "respiratory", "seropositive", "slow potential" ], "approved": true } }, { "type": "Grant", "id": "9395", "attributes": { "award_id": "75N91021C00003-0-9999-1", "title": "CYTOF AND O-LINK ASSESSMENT IN THE `NCI COVID-19 IN CANCER PATIENTS STUDY' (NCCAPS)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-12-23", "end_date": "2021-12-22", "award_amount": 2712342, "principal_investigator": { "id": 25132, "first_name": "SACHA", "last_name": "GNJATIC", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The primary objective of this project is to study the immune response to COVID-19 in patients with cancer by assessing the cellular compartment of the immune system using mass cytometry by CyTOF and cytokines by O-link profiling.", "keywords": [ "COVID-19", "Cancer Patient", "Cytometry", "Immune response", "Immune system", "Link", "Malignant Neoplasms", "Patients", "cytokine" ], "approved": true } }, { "type": "Grant", "id": "12771", "attributes": { "award_id": "75N91021D00017-P00001-759102200003-1", "title": "DATA MANAGEMENT FOR CANCER DIAGNOSIS PROGRAM ACTIVITIES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2023-08-01", "end_date": "2024-07-31", "award_amount": 842461, "principal_investigator": { "id": 28675, "first_name": "DAVE", "last_name": "ANNETTE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1802, "ror": "", "name": "INFORMATION MANAGEMENT SERVICES, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Cancer Institute (NCI) is an institute within the National Institutes of Health (NIH), one of eight agencies that compose the Public Health Service (PHS), Department of Health and Human Services (DHHS). The mission of the NCI is to plan, conduct, and coordinate the National Cancer program and involves (a) research on the causes, detection, diagnosis, prevention, treatment, and palliative care of cancers and on rehabilitation of the cancer patient and (b) demonstration of the effectiveness of cancer control methods and techniques. II. Background The Division of Cancer Treatment and Diagnosis (DCTD) of the NCI has initiated a natural history study, NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study to investigate the course of disease in cancer patients with positive test results for SARS-CoV-2, the virus that causes the disease COVID-19. Across the NCI’s clinical trials networks, patients who enroll will have clinical data, imaging data and longitudinal blood or other biospecimens collected over a two-year period for laboratory analysis. NCI will use its existing Medidata Rave system to acquire and manage the clinical data and the Imaging and Radiation Oncology Core (IROC) to manage the imaging data. Several different kinds of laboratory analyses are planned to investigate biological aspects of the disease, including but not limited to genomics, serology, and immune response, and to examine associations of biological features with clinical variables and outcomes. Laboratory studies will take place at multiple institutions, both at NCI-Frederick and at several non-government academic and commercial laboratories. The data analysis effort will be led by the Biometric Research Program (BRP) in DCTD, in collaboration with the participating laboratories and other members of the study team.", "keywords": [ "2019-nCoV", "Address", "Adopted", "Biological", "Biological Assay", "Biological Markers", "Biometry", "Blood", "COVID-19", "Cancer Control", "Cancer Patient", "Characteristics", "Clinical", "Clinical Data", "Clinical Management", "Clinical Trials", "Clinical Trials Network", "Collaborations", "Communication", "Computers", "Consult", "Consultations", "Contractor", "Custom", "Data", "Data Analyses", "Data Collection", "Data Commons", "Data Element", "Data Files", "Data Security", "Data Set", "Databases", "Detection", "Development", "Diagnosis", "Disease", "Division of Cancer Treatment and Diagnosis", "Documentation", "Effectiveness", "Electronic Mail", "Electronics", "Enrollment", "Ensure", "Event", "Excision", "Extramural Activities", "Failure", "Frequencies", "Generations", "Genomics", "Grant", "Group Meetings", "Human Resources", "Image", "Immune response", "Individual", "Institution", "Laboratories", "Laboratory Study", "Length", "Link", "Logic", "Logistics", "Manuals", "Master of Science", "Medidata", "Methods", "Mission", "Modification", "Molecular Analysis", "Monitor", "Names", "National Cancer Institute", "National Cancer Program", "Natural History", "Online Systems", "Outcome", "Patients", "Performance", "Positive Test Result", "Preparation", "Prevention", "Process", "Production", "Quality Control", "Radiation Oncology", "Recurrence", "Reporting", "Research", "Research Personnel", "Resources", "Secure", "Serology", "Services", "Shipping", "Specific qualifier value", "Specimen", "Statistical Data Interpretation", "Structure", "Support Contracts", "System", "Techniques", "Telephone", "Text", "Time", "United States Dept. of Health and Human Services", "United States National Institutes of Health", "United States Public Health Service", "Update", "Virus", "anticancer research", "application programming interface", "biobank", "cancer diagnosis", "cancer palliative treatment", "cancer rehabilitation", "clinical database", "clinical research site", "data acquisition", "data de-identification", "data exchange", "data management", "data repository", "design", "experience", "falls", "follow-up", "individual responsibility", "meetings", "member", "programs", "sample collection", "statistics", "success", "symposium", "timeline", "working group" ], "approved": true } }, { "type": "Grant", "id": "8132", "attributes": { "award_id": "75N91021F00056-0-0-1", "title": "Laboratory to Perform Assays of Coagulopathy Biomarkers for the National Cancer Institute’s COVID-19 in Cancer Patients Study (NCCAPS)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-03-01", "end_date": "2022-02-28", "award_amount": 405994, "principal_investigator": { "id": 24006, "first_name": "EDWARD", "last_name": "WONG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Lab will conduct coagulopathy assays for NCI to analyze as part of a correlative science objective in NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study, ClinicalTrials.gov Identifier: NCT04387656 https://clinicaltrials.gov/ct2/show/NCT04387656", "keywords": [ "Biological Assay", "Biological Markers", "Blood Coagulation Disorders", "COVID-19", "Cancer Patient", "Laboratories", "National Cancer Institute", "Natural History", "Science" ], "approved": true } }, { "type": "Grant", "id": "9829", "attributes": { "award_id": "75N91021F00056-P00002-0-1", "title": "Laboratory to Perform Assays of Coagulopathy Biomarkers for the National Cancer Institute’s COVID-19 in Cancer Patients Study (NCCAPS)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-03-01", "end_date": "2023-02-28", "award_amount": 155897, "principal_investigator": { "id": 24006, "first_name": "EDWARD", "last_name": "WONG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Lab will conduct coagulopathy assays for NCI to analyze as part of a correlative science objective in NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study, ClinicalTrials.gov Identifier: NCT04387656 https://clinicaltrials.gov/ct2/show/NCT04387656", "keywords": [ "Biological Assay", "Biological Markers", "Blood Coagulation Disorders", "COVID-19", "Cancer Patient", "Laboratories", "National Cancer Institute", "Natural History", "Science" ], "approved": true } }, { "type": "Grant", "id": "14008", "attributes": { "award_id": "75N91021F00056-P00005-0-1", "title": "Laboratory to Perform Assays of Coagulopathy Biomarkers for the National Cancer Institute’s COVID-19 in Cancer Patients Study (NCCAPS)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2023-03-01", "end_date": "2024-02-28", "award_amount": 155897, "principal_investigator": { "id": 24006, "first_name": "EDWARD", "last_name": "WONG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Lab will conduct coagulopathy assays for NCI to analyze as part of a correlative science objective in NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study, ClinicalTrials.gov Identifier: NCT04387656 https://clinicaltrials.gov/ct2/show/NCT04387656", "keywords": [ "Biological Assay", "Biological Markers", "Blood Coagulation Disorders", "COVID-19", "Cancer Patient", "Laboratories", "National Cancer Institute", "Natural History", "Science" ], "approved": true } }, { "type": "Grant", "id": "12418", "attributes": { "award_id": "75N91023C00031-0-9999-1", "title": "TOPIC 425: POSTURE ANALYSIS THROUGH MACHINE LEARNING (PATHML) PHASE II", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2023-09-01", "end_date": "2025-08-31", "award_amount": 2049554, "principal_investigator": { "id": 28366, "first_name": "", "last_name": "", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2100, "ror": "", "name": "SENTIMETRIX, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The availability of low-cost video has tremendous potential to provide new insight into how physical behavior is associated with health, define clinical trial outcomes, and assess physical function within the home, research and clinical environments. The COVID-19 pandemic required a rapid shift to incorporate video-based data collection and clinical visits, establishing the feasibility of using video for clinical outcome assessments (COA). However, there is a lack of software tools to automate and incorporate video into health-related applications. Our Phase I project resulted in a proof-of-concept PathML software prototype that included several sufficiently accurate machine learning models to annotate posture, physical activity intensity, and features of the environment. The Phase II project has two goals. The first goal is to enhance the functionality of the Phase I PathML prototype through innovative machine learning approaches to annotate relevant to physical behavior research taxonomies and UX enhancements that will result in a market-ready tool addressing the needs of physical behavior researchers. Additionally, this project seeks to extend the software to include automatic identification and scoring of clinically relevant COA’s (e.g., 30 second sit-stand test, two-minute walk test), partnering with clinical researchers with expertise in aging, movement disorders, amputees, and cancer rehabilitation.", "keywords": [ "Address", "Aging", "Amputees", "Architecture", "Behavior", "COVID-19 pandemic", "Clinical", "Clinical Trials", "Computer Vision Systems", "Computer software", "Data", "Data Collection", "Data Set", "Environment", "Feedback", "Future", "Goals", "Health", "Home", "Hour", "Infrastructure", "Machine Learning", "Marketing", "Measures", "Modeling", "Movement Disorders", "Outcome", "Patients", "Performance", "Phase", "Physical Function", "Physical Performance", "Physical activity", "Physical assessment", "Population", "Posture", "Research", "Research Personnel", "Software Tools", "System", "Taxonomy", "Testing", "Time", "Training", "Visit", "Walking", "acceptability and feasibility", "cancer rehabilitation", "clinical outcome assessment", "clinically relevant", "cohort", "cost", "health application", "improved", "innovation", "insight", "machine learning model", "novel", "prototype", "telehealth", "tool", "trend", "usability" ], "approved": true } }, { "type": "Grant", "id": "15542", "attributes": { "award_id": "75N91024P00368-0-0-1", "title": "NCI PATTERNS OF CARE (POC) STUDY: DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-05-01", "end_date": "2025-04-30", "award_amount": 63204, "principal_investigator": { "id": 32086, "first_name": "CHARLES", "last_name": "WIGGINS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 761, "ror": "", "name": "UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR", "address": "", "city": "", "state": "NM", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Cancer Institute (NCI) Patterns of Care (POC) studies describe, characterize, and compare practice patterns and treatments provided for cancer in different geographic areas of the United States. POC Studies are conducted periodically, typically annually, to satisfy a congressional directive (under Public Law 100-607, Sec. 413 (a)(2)(C) adopted on November 4, 1988) to the NCI to “assess the incorporation of state-of-the-art cancer treatments into clinical practice and the extent to which cancer patients receive such treatments and include the results of such assessment in the biennial reports…”. To satisfy the directive and to update and enhance the utility of the POC Studies, a working group including representatives from the NCI’s Divisions of Cancer Control and Population Sciences and Cancer Treatment and Diagnosis and a representative from the American Cancer Society was developed to review knowledge gaps in cancer therapy dissemination and to develop priority areas for study. The group reached a consensus that a gap remains regarding factors associated with guideline use of biomarker tests and targeted therapy. Furthermore, the group determined there is limited information about the effects of the COVID-19 pandemic on cancer screening, diagnosis, treatment, and receipt of supportive/palliative care among individuals diagnosed with cancer. For feasibility reasons, the group also recommended that this POC Study be focused specifically on the patterns of care for patients newly diagnosed with prostate or ovarian cancer. This POC Study will also collect data on documentation of palliative care and patient financial impacts of the COVID-19 pandemic. Relevant information on cancer diagnosis, cancer recurrence and metastasis, patterns of care (e.g., utilization of biomarker testing, specific cancer treatments, supportive/palliative care), and patient financial stability shall be abstracted from medical records among patients aged 20 years or older who were diagnosed with prostate or ovarian cancer in 2021.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15541", "attributes": { "award_id": "75N91024P00395-0-0-1", "title": "NCI PATTERNS OF CARE STUDY - DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-05-01", "end_date": "2025-04-30", "award_amount": 91532, "principal_investigator": { "id": 32085, "first_name": "MICHELE", "last_name": "WEST", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 220, "ror": "https://ror.org/036jqmy94", "name": "University of Iowa", "address": "", "city": "", "state": "IA", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Cancer Institute (NCI) Patterns of Care (POC) studies describe, characterize, and compare practice patterns and treatments provided for cancer in different geographic areas of the United States. POC Studies are conducted periodically, typically annually, to satisfy a congressional directive (under Public Law 100-607, Sec. 413 (a)(2)(C) adopted on November 4, 1988) to the NCI to “assess the incorporation of state-of-the-art cancer treatments into clinical practice and the extent to which cancer patients receive such treatments and include the results of such assessment in the biennial reports…”. To satisfy the directive and to update and enhance the utility of the POC Studies, a working group including representatives from the NCI’s Divisions of Cancer Control and Population Sciences and Cancer Treatment and Diagnosis and a representative from the American Cancer Society was developed to review knowledge gaps in cancer therapy dissemination and to develop priority areas for study. The group reached a consensus that a gap remains regarding factors associated with guideline use of biomarker tests and targeted therapy. Furthermore, the group determined there is limited information about the effects of the COVID-19 pandemic on cancer screening, diagnosis, treatment, and receipt of supportive/palliative care among individuals diagnosed with cancer. For feasibility reasons, the group also recommended that this POC Study be focused specifically on the patterns of care for patients newly diagnosed with prostate or ovarian cancer. This POC Study will also collect data on documentation of palliative care and patient financial impacts of the COVID-19 pandemic. Relevant information on cancer diagnosis, cancer recurrence and metastasis, patterns of care (e.g., utilization of biomarker testing, specific cancer treatments, supportive/palliative care), and patient financial stability shall be abstracted from medical records among patients aged 20 years of older who were diagnosed with prostate or ovarian cancer in 2021.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15502", "attributes": { "award_id": "75N91024P00396-0-0-1", "title": "NCI PATTERNS OF CARE STUDY FOR DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-05-01", "end_date": "2025-04-30", "award_amount": 72901, "principal_investigator": { "id": 32048, "first_name": "Jennifer A.", "last_name": "Doherty", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 202, "ror": "https://ror.org/03r0ha626", "name": "University of Utah", "address": "", "city": "", "state": "UT", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Cancer Institute (NCI) Patterns of Care (POC) studies describe, characterize, and compare practice patterns and treatments provided for cancer in different geographic areas of the United States. POC Studies are conducted periodically, typically annually, to satisfy a congressional directive (under Public Law 100-607, Sec. 413 (a)(2)(C) adopted on November 4, 1988) to the NCI to “assess the incorporation of state-of-the-art cancer treatments into clinical practice and the extent to which cancer patients receive such treatments and include the results of such assessment in the biennial reports…”. To satisfy the directive and to update and enhance the utility of the POC Studies, a working group including representatives from the NCI’s Divisions of Cancer Control and Population Sciences and Cancer Treatment and Diagnosis and a representative from the American Cancer Society was developed to review knowledge gaps in cancer therapy dissemination and to develop priority areas for study. The group reached a consensus that a gap remains regarding factors associated with guideline use of biomarker tests and targeted therapy. Furthermore, the group determined there is limited information about the effects of the COVID-19 pandemic on cancer screening, diagnosis, treatment, and receipt of supportive/palliative care among individuals diagnosed with cancer. For feasibility reasons, the group also recommended that this POC Study be focused specifically on the patterns of care for patients newly diagnosed with prostate or ovarian cancer. This POC Study will also collect data on documentation of palliative care and patient financial impacts of the COVID-19 pandemic. Relevant information on cancer diagnosis, cancer recurrence and metastasis, patterns of care (e.g., utilization of biomarker testing, specific cancer treatments, supportive/palliative care), and patient financial stability shall be abstracted from medical records among patients aged 20 years of older who were diagnosed with prostate or ovarian cancer in 2021.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1391, "pages": 1419, "count": 14184 } } }